The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- The First Affiliated Hospital, Sun Yat-sen University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 12 to 65 years;
Myasthenia gravis:
- Patients who are diagnosed as generalized or ocular myasthenia gravis
- have experienced extended thymectomy (including thymic hyperplasia and thymoma), no significant complications in 6 months after operation , and does not received any immunosuppressants or glucocorticoids treatments.
- do not applied in plasmapheresis or immunoglobulins treatment during 3 months .
- women of child-bearing period do not have a plan of pregnant for at least 3 year.
- Written consent of the patient, after informing
Exclusion Criteria:
- The liver , kidney or glycometabolic function is abnormal
- Seriously complications, such as infection or symptom in central nervous system,
- The patients who suffering from malignancy or a history of malignancy, a variety of sexually transmitted diseases and HIV infection, tuberculosis infection, and other condition which need to prohibit the use of immunosuppressive patients.
- Be allergic to leflunomide, azathioprine
- Pregnant or suckling period woman
- Accompanied with mental disorders and have difficult to communication
- Experienced myasthenia crisis in 3 months.
- suffering from clear cardiopulmonary functional and brain abnormalities
- Have a history of refractory hypertension or peptic ulcer .
- One of the white blood cells, hemoglobin, and platelet count obvious abnormalities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Azathioprine
cholinesterase inhibitors+Glucocorticoid +Azathioprine
|
The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d).
Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
|
|
Active Comparator: Leflunomide
cholinesterase inhibitors+glucocorticoid+Leflunomide
|
The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d).
Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child.
if no adverse events occurred , maintain the dose until 48 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the percent of achieving good response
Time Frame: 144 weeks
|
Pharmacologic Remission (PR) was the primary efficacy endpoint observed.
Record the time the patient appears from the time of medication to the time of PR, and calculate the percentage of PR patients in each arm.
Criteria for PR: The patient has had no symptoms or signs of MG for at least 1 year and continues to take some form of therapy for MG.
There is no weakness of any muscle on careful examination by someone skilled in the evaluation of neuromuscular disease.
Isolated weakness of eyelid closure is accepted.
Patients taking cholinesterase inhibitors are excluded from this category because their use suggests the presence of weakness.
|
144 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The changes of the disease severity and the antibody titer during the follow-up
Time Frame: 144 weeks
|
The magnitude by which QMG or ADL scores are reduced.
Total amount of steroid used during the follow-up.
Level of the acetylcholine receptor antibody.
|
144 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Weibin Liu, Doctor, First Affiliated Hospital, Sun Yat-Sen University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Leflunomide
- Azathioprine
Other Study ID Numbers
Other Study ID Numbers
- ZS-LEF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.